Valeant Pharmaceuticals International Inc. (VRX) Stock Rating Reaffirmed by Wells Fargo & Co.

Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “underperform” rating reissued by equities research analysts at Wells Fargo & Co. in a research note issued to investors on Friday. They presently have a $11.50 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $19.50. Wells Fargo & Co.’s target price would suggest a potential downside of 37.33% from the company’s previous close.

VRX has been the topic of a number of other research reports. Deutsche Bank AG cut their target price on Valeant Pharmaceuticals International from $30.00 to $29.00 and set a “hold” rating on the stock in a research report on Friday, October 14th. Morgan Stanley reissued a “positive” rating on shares of Valeant Pharmaceuticals International in a research report on Friday, August 19th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, October 25th. RBC Capital Markets set a $36.00 price objective on Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Friday, August 19th. Finally, Royal Bank Of Canada cut their price objective on Valeant Pharmaceuticals International from $36.00 to $35.00 and set a “sector perform” rating on the stock in a research report on Wednesday, October 12th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has a consensus rating of “Hold” and a consensus target price of $39.63.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 18.35 on Friday. The stock has a 50 day moving average price of $20.71 and a 200-day moving average price of $24.35. Valeant Pharmaceuticals International has a 52-week low of $13.77 and a 52-week high of $119.87. The firm’s market cap is $6.38 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. The firm earned $2.48 billion during the quarter, compared to analysts’ expectations of $2.49 billion. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 43.81%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.74 EPS. On average, equities analysts anticipate that Valeant Pharmaceuticals International will post $5.43 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in VRX. Legal & General Group Plc raised its stake in shares of Valeant Pharmaceuticals International by 2.8% in the first quarter. Legal & General Group Plc now owns 1,209,137 shares of the specialty pharmaceutical company’s stock worth $31,830,000 after buying an additional 33,247 shares during the period. LPL Financial LLC raised its stake in shares of Valeant Pharmaceuticals International by 65.5% in the first quarter. LPL Financial LLC now owns 91,050 shares of the specialty pharmaceutical company’s stock worth $2,616,000 after buying an additional 36,046 shares during the period. Seven Eight Capital LLC purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $374,000. Academy Capital Management Inc. TX raised its stake in shares of Valeant Pharmaceuticals International by 13.4% in the third quarter. Academy Capital Management Inc. TX now owns 649,959 shares of the specialty pharmaceutical company’s stock worth $15,956,000 after buying an additional 76,638 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Valeant Pharmaceuticals International by 11.9% in the second quarter. Vanguard Group Inc. now owns 5,917,325 shares of the specialty pharmaceutical company’s stock worth $119,175,000 after buying an additional 631,211 shares during the period. Institutional investors and hedge funds own 67.13% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2016 Mideast Time.